Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Carroll KM, Weiss RD.

Am J Psychiatry. 2017 Aug 1;174(8):738-747. doi: 10.1176/appi.ajp.2016.16070792. Epub 2016 Dec 16. Review.

2.

Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.

Ling W, Chang L, Hillhouse M, Ang A, Striebel J, Jenkins J, Hernandez J, Olaer M, Mooney L, Reed S, Fukaya E, Kogachi S, Alicata D, Holmes N, Esagoff A.

Addiction. 2014 Sep;109(9):1489-500. doi: 10.1111/add.12608. Epub 2014 Jul 8.

3.

Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.

Carroll KM, Kiluk BD, Nich C, DeVito EE, Decker S, LaPaglia D, Duffey D, Babuscio TA, Ball SA.

Drug Alcohol Depend. 2014 Apr 1;137:3-19. doi: 10.1016/j.drugalcdep.2014.01.012. Epub 2014 Jan 31. Review.

4.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.

5.

Including all individuals is not enough: lessons for intention-to-treat analysis.

White IR, Carpenter J, Horton NJ.

Clin Trials. 2012 Aug;9(4):396-407. doi: 10.1177/1740774512450098. Epub 2012 Jul 2.

6.

Working Inside for Smoking Elimination (Project W.I.S.E.) study design and rationale to prevent return to smoking after release from a smoke free prison.

Clarke JG, Martin RA, Stein L, Lopes CE, Mello J, Friedmann P, Bock B.

BMC Public Health. 2011 Oct 5;11:767. doi: 10.1186/1471-2458-11-767.

7.

A methodological analysis of randomized clinical trials of computer-assisted therapies for psychiatric disorders: toward improved standards for an emerging field.

Kiluk BD, Sugarman DE, Nich C, Gibbons CJ, Martino S, Rounsaville BJ, Carroll KM.

Am J Psychiatry. 2011 Aug;168(8):790-9. doi: 10.1176/appi.ajp.2011.10101443. Epub 2011 May 2.

8.

Addressing missing data in clinical trials.

Fleming TR.

Ann Intern Med. 2011 Jan 18;154(2):113-7. doi: 10.7326/0003-4819-154-2-201101180-00010.

9.

Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials.

Ten Have TR, Normand SL, Marcus SM, Brown CH, Lavori P, Duan N.

Psychiatr Ann. 2008 Dec;38(12):772-783. No abstract available.

10.

Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD.

Young RC, Schulberg HC, Gildengers AG, Sajatovic M, Mulsant BH, Gyulai L, Beyer J, Marangell L, Kunik M, Ten Have T, Bruce ML, Gur R, Marino P, Evans JD, Reynolds CF 3rd, Alexopoulos GS.

Bipolar Disord. 2010 Feb;12(1):56-67. doi: 10.1111/j.1399-5618.2009.00779.x.

11.

Enhancing clinical trial design of interventions for posttraumatic stress disorder.

Leon AC, Davis LL.

J Trauma Stress. 2009 Dec;22(6):603-11. doi: 10.1002/jts.20466.

12.

Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues.

Lavori PW, Brown CH, Duan N, Gibbons RD, Greenhouse J.

Psychiatr Ann. 2008 Dec 1;38(12):784-792. No abstract available.

13.

Missing Data in Longitudinal Trials - Part B, Analytic Issues.

Siddique J, Brown CH, Hedeker D, Duan N, Gibbons RD, Miranda J, Lavori PW.

Psychiatr Ann. 2008 Dec 1;38(12):793-801.

14.

A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M; STOP-PD Group.

Arch Gen Psychiatry. 2009 Aug;66(8):838-47. doi: 10.1001/archgenpsychiatry.2009.79. Erratum in: Arch Gen Psychiatry. 2011 Jun;68(6):626.

15.

Serenoa repens for benign prostatic hyperplasia.

Tacklind J, MacDonald R, Rutks I, Wilt TJ.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001423. doi: 10.1002/14651858.CD001423.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD001423.

16.

Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up.

Kolko DJ, Dorn LD, Bukstein OG, Pardini D, Holden EA, Hart J.

J Abnorm Child Psychol. 2009 Jul;37(5):591-609. doi: 10.1007/s10802-009-9303-7.

17.

The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials.

Hedden SL, Woolson RF, Carter RE, Palesch Y, Upadhyaya HP, Malcolm RJ.

J Subst Abuse Treat. 2009 Jul;37(1):54-63. doi: 10.1016/j.jsat.2008.09.011. Epub 2008 Nov 13.

18.

The impact of analytic method on interpretation of outcomes in longitudinal clinical trials.

Prakash A, Risser RC, Mallinckrodt CH.

Int J Clin Pract. 2008 Aug;62(8):1147-58. doi: 10.1111/j.1742-1241.2008.01808.x. Epub 2008 Jun 28.

19.

Methodological issues in current antipsychotic drug trials.

Leucht S, Heres S, Hamann J, Kane JM.

Schizophr Bull. 2008 Mar;34(2):275-85. doi: 10.1093/schbul/sbm159. Epub 2008 Jan 29. Review.

20.

Methods for testing theory and evaluating impact in randomized field trials: intent-to-treat analyses for integrating the perspectives of person, place, and time.

Brown CH, Wang W, Kellam SG, Muthén BO, Petras H, Toyinbo P, Poduska J, Ialongo N, Wyman PA, Chamberlain P, Sloboda Z, MacKinnon DP, Windham A; Prevention Science and Methodology Group.

Drug Alcohol Depend. 2008 Jun 1;95 Suppl 1:S74-S104. doi: 10.1016/j.drugalcdep.2007.11.013. Epub 2008 Jan 22.

Supplemental Content

Support Center